Tyson Saimy Le

Mr. Tyson Saimy Le

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Processes
Verified
Journal Article
Open access
PDF file
HNHamdah Al Nebaihi
Hamdah Al Nebaihi
TLTyson Saimy Le
Tyson Saimy Le
Neal DaviesNeal Davies
Neal Davies
DBDion Brocks
Dion Brocks
A selective and sensitive assay was developed for colchicine in rat specimens. Colchicine and its deuterated analog (as internal standard, IS) were extracted from rat specimens (minimal 0.1 mL plasma, whole blood, or urine) using liquid-liquid extraction with n-hexane:dichloromethane:isopropanol. The mobile phase (formic acid: ammonium acetate: methanol) was pumped with uniform flow through an octadecylsilane analytical column. Detection was carried out by electrospray positive ionization in the multiple-reaction monitoring mode. The assay (total run time 96.8%. The intra- and inter-day coefficients of variation were ˂15%, with lower limits of quantitation of 0.5 ng/mL in 0.1 mL of rat plasma. The method also provided the same lower limits of quantitation in urine and whole blood with 0.1 mL volumes, and 0.1 ng/mL using 0.5 mL of rat plasma. The blood-to-plasma ratio was >1. Rats had measurable colchicine blood concentrations for at least 24 h after intravenous doses of 0.1 mg/kg. The method possessed suitable measures of sensitivity and selectivity for detecting colchicine in several specimen types in rats given low doses.

3 February 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
KIkhaled sobhy ibrahim
khaled sobhy ibrahim
TLTyson Saimy Le
Tyson Saimy Le
SMSherif Hanafy Mahmoud
Sherif Hanafy Mahmoud
Background: Piperacillin (Pip)/tazobactam (Taz) is a broad-spectrum antimicrobial agent that has been commonly used in the intensive care unit for severe and life-threatening infections. Recent evidence suggests that therapeutic drug monitoring (TDM) for Pip could be beneficial in clinical practice to facilitate dose optimization and increase the odds of treatment success. The aim was to develop and validate a sensitive and simple high-performance liquid chromatography (HPLC) method for the simultaneous quantification of Pip and Taz in human plasma. Methods: Samples (0.3 mL) were deproteinized with acetonitrile. The supernatant was evaporated and then reconstituted and injected into the HPLC. The chromatographic analysis was carried out by using the C18 column and gradient elution with the acetonitrile:water mobile phase mixture with 0.1% trifluoracetic acid at a flow rate of 0.8 mL/min using a UV detector at 218 nm. Results: The method had acceptable linearity (r2 > 0.99) over the concentration ranges of 0.5–400 μg/mL and 1–100 μg/mL for Pip and Taz, respectively. The method demonstrated acceptable inter- and intra-day precision and accuracy within ±20% with adequate stability results. Conclusion: The developed method is sensitive and simple and utilizes simple sample preparation and elution steps, making it suitable and practical for Pip/Taz TDM.

22 April 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
SZShengnan Zhao
Shengnan Zhao
YZYuanheng Zhao
Yuanheng Zhao
JZJieyu Zuo
Jieyu Zuo
TLTyson Saimy Le
Tyson Saimy Le
JKJeerakit Kerdsiri
Jeerakit Kerdsiri
Raimar LöbenbergRaimar Löbenberg
Raimar Löbenberg

5 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MYMalaz Yousef
Malaz Yousef
COConor O'Croinin
Conor O'Croinin
TLTyson Saimy Le
Tyson Saimy Le
CPChulhun Park
Chulhun Park
JZJieyu Zuo
Jieyu Zuo
Raimar LöbenbergRaimar Löbenberg
Raimar Löbenberg
Drug absorption via chylomicrons holds significant implications for both pharmacokinetics and pharmacodynamics. However, a mechanistic understanding of predicting in vivo intestinal lymphatic uptake remains largely unexplored. This study aimed to delve into the intestinal lymphatic uptake of drugs, investigating both enhancement and inhibition using various excipients through our previously established in vitro model. It also examined the applicability of the model by assessing the lymphatic uptake enhancement of a lymphotropic formulation with linoleoyl polyoxyl-6 glycerides using the same model. The model successfully differentiated among olive, sesame, and peanut oils in terms of lymphatic uptake. However, it did not distinguish between oils containing long-chain fatty acids and coconut oil. Coconut oil, known for its abundance of medium-chain fatty acids, outperformed other oils. This heightened uptake was attributed to the superior emulsification of this oil in artificial chylomicron media due to its high content of medium-chain fatty acids. Additionally, the enhanced uptake of the tested formulation with linoleoyl polyoxyl-6 glycerides underscored the practical applicability of this model in formulation optimization. Moreover, data suggested that increasing the zeta potential of Intralipid® using sodium lauryl sulfate (SLS) and decreasing it using (+/−) chloroquine led to enhanced and reduced uptake in the in vitro model, respectively. These findings indicate the potential influence of the zeta potential on intestinal lymphatic uptake in this model, though further research is needed to explore the possible translation of this mechanism in vivo.